We performed a retrospective review of patients diagnosed with CIDP, DSP and CIDP+DSP (responsive to immunotherapy) and examined differences in CMAP duration and TD at baseline. This evidence concerns the gene DSP and chronic inflammatory demyelinating polyradiculoneuropathy.